StemRIM Inc. (JP:4599) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
StemRIM Inc. has commenced a Phase 2 clinical trial for its regenerative medicine product, Redasemtide, targeting ischemic cardiomyopathy at Osaka University Hospital. This trial aims to evaluate the efficacy and safety of the treatment in patients who have undergone coronary artery bypass grafting, with results expected to be monitored 52 weeks post-treatment. Despite this development, it is not anticipated to impact the company’s financial results for the current fiscal year.
For further insights into JP:4599 stock, check out TipRanks’ Stock Analysis page.